

Home - MOP

[View all](#)

**KISQALI® - ribociclib**

[Product Information](#)

**KESIMPTA®▼ - ofatumumab**

[Product Information](#)

**LEQVIO®▼ - inclisiran**

[Product Information](#)

**COSENTYX® - secukinumab in Dermatology**

[Product information](#)

**COSENTYX® - secukinumab in Rheumatology**

[Product information](#)

**JAKAVI® - ruxolitinib**

[Product Information](#)

**SCEMBLIX®▼ - asciminib**

[Product Information](#)



**FABHALTA®▼ - iptacopan**

[Product information](#)



## **Reporting side-effects**

If you get side-effects with any medication you are taking, talk to your doctor, pharmacist or nurse. This includes any possible side-effects not listed in the information leaflet that comes in the pack. ▼ The medicine referred to in this material is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side-effects you may get. Please see [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard) for instructions on how to report side-effects.

## **Reporting side-effects**

If you get side-effects with any medication you are taking, talk to your doctor, pharmacist or nurse. This includes any possible side-effects not listed in the information leaflet that comes in the pack. You can report side-effects via the Yellow Card Scheme at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard).

By reporting side-effects you can help provide more information on the safety of your medication.

---

**Source URL:** <https://www.pro.novartis.com/uk-en/public>